Allopurinol in renal ischemia

Journal of Investigative Surgery

Volumn 27, Issue 5, 2014, Pages 304-316

  Prieto Moure, Beatriz ^a   Carabén Redaño, Anna ^a   Aliena Valero, Alicia ^a   Cejalvo, Dolores ^a   Toledo, Alexander H ^b,c   Flores Bellver, Miguel ^a   Martínez Gil, Natalia ^a   Toledo Pereyra, Luis H ^d   Lloris Carsí, José Miguel ^a  

^a UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Allopurinol; Free radicals; Ischemia; NF kB; Renal; Reperfusion; TNF ; Xanthine oxidase

Indexed keywords

ALLOPURINOL; CALCIUM CHANNEL; CELL ADHESION MOLECULE; ENALAPRIL; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HYPOXANTHINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; XANTHINE OXIDASE; CYTOKINE; ENZYME INHIBITOR; REACTIVE OXYGEN METABOLITE; SCAVENGER; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIOXIDANT ACTIVITY; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; KIDNEY ISCHEMIA; LIPID PEROXIDATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN SECRETION; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SYSTEMATIC REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INJURIES; ISCHEMIA; KIDNEY; METABOLISM; VASCULARIZATION;

ALLOPURINOL; ANIMALS; CALCIUM CHANNELS; CELL ADHESION MOLECULES; CYTOKINES; ENZYME INHIBITORS; FREE RADICAL SCAVENGERS; HUMANS; IMMUNE SYSTEM; ISCHEMIA; KIDNEY; LIPID PEROXIDATION; METABOLIC NETWORKS AND PATHWAYS; NF-KAPPA B; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; RECEPTORS, TUMOR NECROSIS FACTOR; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA; XANTHINE OXIDASE;

EID: 84907021901     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941939.2014.911395     Document Type: Review

References (113)

1. Elion GB, Ide WS, Hitchings GH. The ultraviolet absorption spectra of thiouracils. J Am Chem Soc. 1946;68:2137-2140.
2. Hitchings GH, Elion GB, Falco EA, et al. Studies on analogs of purines and pyrimidines. Ann N Y Acad Sci. 1950;52:1318-1335.
3. Elion GB, Callahan SW, Hitchings GH, et al. Experimental clinical and metabolic studies of thiopurines. Cancer Chemother. 1962;16:197-202.
4. Pacher P, Nivorozhkin A, Szab? C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after discovery of allopurinol. Pharmacol Rev. 2006;58: 87-114.
5. Murrel GAC, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet. 1986;11:343-353.
6. Suzuki I, Yamauchi T, Onuma M, et al. Allopurinol, an inhibitor of uric acid synthesis-can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today. 2009;45:363-378.
7. Crowell JW, Jones CE, Smith EE. Effect of allopurinol on hemorrhagic shock. Am J Physiol. 1969;216:744-748.
8. De Wall RA, Vasko KA, Stanley EL, et al. Responses of the ischemic myocardium to allopurinol. Am Heart J. 1971;82:362-370.
9. Vasko KA, DeWall RA, Riley AM. Effect of allopurinol in renal ischemia. Surgery. 1972;71:787-790.
10. Toledo-Pereyra LH, Najarian JS. Total recovery of ischemic kidneys treated with allopurinol before transplantation. Surg Forum. 1973;24:302-304.
11. Quebbemann AJ, Cumming JD, Shideman JR, et al. Synthesis of uric acid in isolated normothermic perfused mongrel and Dalmatian dog kidneys. Am J Physiol. 1975;228(3):959-963.
12. Toledo-Pereyra LH, Simmons RL, Najarian JS. Protection of the ischemic liver by donor pretreatment before transplantation. Am J Surg. 1975;129(5):513-517.
13. Lindsay WG, Toledo-Pereyra LH, Foker JE, et al.Metabolic myocardial protection with allopurinol during cardiopulmonary bypass and aortic cross-clamping. Surg Forum. 1975;26:259-260.
14. Cunningham SK, Keaveny TV, Fitzgerald P. Effect of allopurinol on tissue ATP, ADP, and AMP concentrations in renal ischaemia. Br J Surg. 1974;61(7):562-565.
15. Keel CE, Wang Z, Colli J, et al. Protective effects of reducing renal ischemia-reperfusion injury during renal hilar clamping: use of allopurinol as a nephroprotective agent. Urology. 2013;81(1):210.e5-e10
16. Hansson R, Johansson S, Jonsson O. Kidney protection by pretreatmentwith free radical scavengers and allopurinol: renal function at recirculation after warm ischaemia in rabbits. Clin Sci. 1986;71(3):245-251.
17. Vaughan DL, Wickramasinghe YA, Russell GI, et al. Is allopurinol beneficial in the prevention of renal ischaemiareperfusion injury in the rat?: evaluation by near-infrared spectroscopy. Clin Sci. 1995;88:359-364.
18. Alatas O, SahinA, Colak O, et al. Beneficial effects of allopurinol on glutathione levels and glutathione peroxidase activity in rat ischaemic acute renal failure. J IntMed Res. 1996;24(1):33-39.
19. Gupta PC, Matsushita M, Oda K, et al. Attenuation of renal ischemia-reperfusion injury in rats by allopurinol and prostaglandin E1. Eur Surg Res. 1998;30(2):102-107.
20. Marx A, Heberer M, Gale J, et al. Reduction of renal reperfusion damage following warm ischemia by allopurinol and superoxide dismutase. Helv Chir Acta. 1989;56(4):539-542.
21. Radovic M, Miloradovic Z, Popovic T, et al. Allopurinol and enalapril failed to conserve urinary NOx and sodium in ischemic acute renal failure in spontaneously hypertensive rats. Am J Nephrol. 2006;26(4):388-399.
22. Tripatara P, Patel NS, Webb A, et al. Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol. 2007;18(2):570-580.
23. Snchez-Lozada LG, Tapia E, Santamar J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67(1):237-247.
24. Yelken B, Caliskan Y, Gorgulu N, et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol. 2012;77(4):275-282.
25. Baker GL, Autor AP, Corry RJ. Effect of allopurinol on kidneys after ischemia and reperfusion. Curr Surg. 1985;42(6):466-469.
26. Owens ML, Lazarus HM, Wolcott MW, et al. Allopurinol and hypoxanthine pretreatment of canine kidney donors. Transplantation. 1974;17:424-426.
27. Castaneda MP, Swiatecka-Urban A, Mitsnefes MM, et al. Activation of mitochondrial apoptotic pathways in human renal allografts after ischemia-reperfusion injury. Transplantation. 2003;76, 50-54.
28. Devarajan, P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006;17:1503-1520.
29. Elion GB, Kovensky, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966;15:863-880.
30. Hernndez-Baro C, Tamara JA, Toledo-Pereyra LH. Isquemia heptica. Conceptos bsicos sobre su fisiopatology tratamiento. Ciruǵa y cirujanos. 1990;57:241-249.
31. Nauta RJ, Tsimoyiannis E, Uribe M, et al. Oxygen-derived free radicals in hepatic ischemia and reperfusion injury in the rat. Gynecol Obstet. 1990;171:120-125.
32. Schoenberg MH, Paes E. Intestinal ischemia and reperfusion. Prog Appl Microcirc. 1989;13:109-111.
33. Arnold PE, Lumlertgul D, Burke TJ, et al. In vitro versus in vivo mitochondrial calcium loading in ischemic acute renal failure. Am J Physiol. 1985;248:F845.
34. Greene EL, Paller MS. Calcium and free radical in hypoxia/reoxygenation injury of renal epithelial cells. Am J Physiol Renal Physiol. 1994;266:F13-F20.
35. Godin DV, Bhimji S. Effects of allopurinol on myocardial ischemic injury induced by coronary artery ligation and reperfusion. Biochem Pharmacol. 1987;36:2101-2107.
36. Shapiro JI, Cheung C, Itabashi A, et al. The effect of verapamil on renal function after warm and cold ischemia in the isolated perfused rat kidney. Transplantation. 1985;40:596.
37. Hertle L, Garthoff. Calcium channel blocker nisoldipine limits ischemic damage in rat kidney. J Urol. 1985;134:1251.
38. Kennedy SE, Erlich JH. Murine renal ischemia-reperfusion injury. Nephrology. 2008;13:390-396.
39. Gourdin MJ, Bree B, De Kock M. The impact of ischaemia-reperfusion on the blood vessel. Eur J Anaesthesiology. 2009;26, 537-547.
40. Zager RA, Johnson AC, Naito M, et al. Maleate nephrotoxicity: mechanisms of injury and correlates with ischemic/hypoxic tubular cell death. Am J Physiol Renal Physiol. 2008;294(1):F187-F197.
41. Ratych RE, Bulkley GB, Williams GM. Ischemia/reperfusion injury in the kidney. Prog Clin Biol Res. 1986;224:263-289.
42. Hueteraux C, Lauritzen I, Widmann C, et al. Essential role of adenosine, adenosine A1 receptors and ATP sensitive K+ channel in cerebral ischaemic preconditioning. Proc Natl Acad Sci USA. 1995;92:4666-4670.
43. Gibson T, Simmonds HA, Potter C, et al. A controlled study of the effect of long term allopurinol treatment on renal function in gout. Adv Exp Med Biol. 1980;122A:257-262.
44. Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest. 1984;74:1156-1164.
45. Greene EL, Paller MS. Xanthine oxidase produces O2-in posthypoxic injury of renal epithelial cells. Am J Physiol. 1992;263:251-255.
46. Yun Y, Duan WG, Chen P, et al. Ischaemic postconditioning modified renal oxidative stress and lipid peroxidation caused by ischaemic reperfusion injury in rats. Transplant Proceed. 2009;41:3597-3602.
47. Baker GL, Corry RJ, Autor AP, et al. Oxygen free radicals induced damage in kidneys subjected to warm ischemia and reperfusion: protective effect of superoxide dismutase. Ann Surg. 1985;202:628-641.
48. Sameshima T, Miyao J, Oda T, et al. Effects of allopurinol on renal damage following renal ischemia. Masui. 1995;44(3):349-356.
49. Namazi MR. Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. Int Immunopharmacol. 2004;4(3):349-353.
50. Thurman JM, Ljubanovic D, Royer PA, et al. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003;170:1517-1523.
51. Leemans JC, Stokman G, Claessen N, et al. Renalassociated TLR-2mediates ischemia/reperfusion injury in the kidney. J Clin Invest. 2005;115:2894-903.
52. Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007;117:2847-2859.
53. Hoke TS, Douglas IS, Klein CL, et al. Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol. 2007;18(1):155-164.
54. Thurman JM, Lenderink AM, Royer PA, et al. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ischemia/reperfusion. J Immunol. 2007;178:1819-1828.
55. Kelly KJ, Williams WW, Jr, Colvin RB, et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest. 1996;97:1056-1063.
56. Lee S, Huen S, Nishio S, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22:317-326.
57. Amura CR, Renner B, Lyubchenko T, et al. Complement activation and toll-like receptor-2 signaling contribute to cytokine production after renal ischemia/reperfusion. Mol Inmmunol. 2012;52(3-4):249-257.
58. Ferrari R, Ceconi C, Curello S, et al. Role of oxygen free radicals in ischemic and reperfused myocardium. Am J Clin Nutr. 1991;53:215S-222S.
59. Tirmenstein MA, Reed DJ. Characterization of glutathione-dependent inhibition of lipid peroxidation of isolated rat liver nuclei. Archs Biochem Biophys. 1988;266:1-11.
60. Domanska-Janik K, Bourre JM. Effect of lipid peroxidation on Na+, K+-ATPase, 5'-nucleotidase and CNPase inmouse brain myelin. Biochim Biophys Acta. 1990;1034:200-206.
61. Aricioglu A, Aydin S, Turkozkan N. The effect of allopurinol on Na+K+ATPase related lipid peroxidation in ischemic and reperfused rabbit kidney. Gen Pharmacol. 1994;25(2):341-344.
62. Goligorsky MS. "Whispers and shouts in the pathogenesis of acute renal ischaemia". Nephrol Dial Transplant. 2005;20:261-266.
63. Hu QH, Zhang X, Pan Y, et al. Allopurinol, quercetin and routine ameliorate renal NLRP3 inflammasome activation and lipic accumulation in fructose-fed rats. Biochem Pharmacol. 2012;84(1):113-125.
64. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med. 1993;21:S447-S463.
65. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45-65.
66. Perry BC, Soltys D, Toledo AH, et al. Tumor necrosis factor-α in liver ischemia/reperfusion injury. J Invest Surg. 2011;24:178-188.
67. Corda S, Laplace C, Vicault E, et al. Rapid reactive oxygen species production by mitochondrial in endothelial cells exposed to tumor necrosis factor-α is mediated by ceramide. Am J Respir Cell Mol Biol. 2001;24(6):762-768.
68. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487-501.
69. Naismith JH, Sprang SR. Modularity in the TNF-receptor family. Trends Biochem Sci. 1998;23:74-79.
70. Banner DW, D'Arcy A, JanesW, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell. 1993;73:431-445.
71. Chan FK, Chun HJ, Zheng L et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351-2354.
72. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793-802.
73. Sun HY, Wang NP, Halkos M, et al. Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Apoptosis. 2006;11:1583-1593.
74. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NFkappa B activation. Cell. 1995;81:495-504.
75. Zhang J, Cado D, Chen A, et al. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 1998;392: 296-300.
76. Juo P, Woo MS, Kuo CJ, et al. FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ. 1999;10:797-804.
77. Roth E, Hejjel L, Jaberansari MT, et al. The role of free radicals in endogenous adaptation and intracellular signals. Exp Clin Cardiol. 2004;9:13-16.
78. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Hepatology. 2007;97:738-774.
79. Hensley K, Robinson KA, Gabbita SP, et al. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med. 2000;28:1456-1462.
80. Rachmat FD, Rachmat J, Sastroasmoro S, et al. Effect of allopurinol on oxidative stress and hypoxic adaptation response during surgical correction of tetralogy of fallot. Acta Med Indones. 2013;45(2):94-100.
81. Kin H, Wang NP, Mykytenko J, et al. Inhibition of myocardial apoptosis by postconditioning is associated with attenuation of oxidative stress-mediated nuclear factor-kappa B translocation and TNF-α release. Shock. 2008;29:761-768.
82. Jefayri MK, Grace PA, Mathie RT. Attenuation of reperfusion injury by renal ischaemic preconditioning: the role of nitric oxide. Ireland BJU International. 2000;85:1007-1013.
83. Rodrez-Reynoso S, Leal C, Portilla E, et al. Effect of exogenous melatonin on hepatic energetic status during ischemia/reperfusion: possible role of tumor necrosis factor-α and nitric oxide. J Surg Research. 2001;100:141-149.
84. Liu P, Xu B, Spokas E, et al. Role of endogenous nitric oxide in TNF-α and IL-1β generation in hepatic ischemia/reperfusion. Shock. 2000;13:217-223.
85. Legrand M, Almac E, Mik EG, et al. L-NIL prevents renal microvascular hypoxia and increase of renal oxygen consumption after ischemia-reperfusion in rats. Am J Physiol Renal Physiol. 2009;296:F1109-F1117.
86. Zhang C, Hein TW, Wang W, et al. Activation of JNK and xanthine oxidase by TNF-alpha impairs nitric oxidemediated dilation of coronary arterioles. JMol Cell Cardiol. 2006;40(2):247-257.
87. Myers SI, Wang L, Liu F, et al. Oxygen-radical regulation of renal blood flow following suprarenal aortic clamping. J Vasc Surg. 2006;43:577-586.
88. Netea MG, Kullberg BJ, Block WL, et al. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide in neutropenic mice. Blood. 1997;89:577-582.
89. Chaplin DD, Fu Y. Cytokine regulation of secondary lymphoid organ development. Curr Opin Immunol. 1998;10:289-297.
90. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patientswith rheumatoid arthritis. Arthritis Rheum. 2000;43:38-47.
91. Teoh NC, Farrel GC. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol. 2003;18:891-902.
92. Suzuki S, Toledo-Pereyra LH. Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury. J Surg Res. 1994;57:253-258.
93. Ilhan H, Alatas O, Tokar B. Effects of the anti-ICAM-1 monoclonal antibody, allopurinol, and methylene blue on intestinal reperfusion injury. J Pediatr Surg.2003;38:1591-1595.
94. Hatano E. Tumor necrosis factor signaling in hepatocyte apoptosis. J Gastroenterol Hepatol. 2007;22(Suppl. 1):S43-S44.
95. Chen G, Cao P, Goeddel DV. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell. 2002;9:401-410.
96. Yamaoka S, Courtois G, Bessia C. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell. 1998;93:1231-1240.
97. Rothwarf DM, Zandi E, Natoli G, et al. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature. 1998;395:297-300.
98. Harhaj EW, Good L, Xiao G, et al. Somatic mutagenesis studies of NF-kappa B signaling in human T cells: evidence for an essential role of IKK gamma in NF-kappa B activation by T-cell costimulatory signals and HTLV-I Tax protein. Oncogene. 2000;19:1448-1456.
99. Mercurio F, Murray BW, Shevchenko A, et al. IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol Cell Biol. 1999;19:1526-1538.
100. Deckert-Schluter M, Bluethmann H, Rang A, et al. (1998) Crucial role of TNF receptor type 1 (p55), but not of TNF receptor type 2 (p75), inmurine toxoplasmosis. J Immunol. 1998;160:3427-3436.
101. White LE, Santora RJ, Cui Y, et al. TNFR-1-dependent pulmonary apoptosis during ischemic acute kidney injury. Am J Physiol Lung Cell Mol Physiol. 2012;303:L449-L459.
102. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NFkappaB activation. Science. 1999;278:860-866.
103. DiDonato JA, Hayakawa M, Rothwarf DM, et al. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 1997;388:548-554.
104. Zandi E, Rothwarf DM, Delhase M, et al. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell. 1997;91:243-252.
105. Hasson R, Gustafsson O, Jonsson S, et al. Effect of xanthine oxidase inhibition on renal circulation after ischemia. Transpl P. 1982;14:51-58.
106. Zwemer CF, Shoemaker JL, Jr, Hazard SW, III, et al. Hyperoxic reperfusion exacerbates postischemic renal dysfunction. Surgery. 2000;128(5):815-821.
107. Rhoden E, Teloken C, Lucas M, et al. Protective effect of allopurinol in the renal ischemia-reperfusion in uninephrectomized rats. Gen Pharmacol. 2000;35(4):189-193.
108. Willgoss DA, Zhang B, Gob GC, et al. Repetitive brief ischemia: intermittent reperfusion during ischemia ameliorates the extent of injury in the perfused kidney. Ren Fail. 2003;25(3):379-395.
109. Peto K, Olh VA, Brth E, et al. Determination of urinary NAG to detect renal ischemia-reperfusion injury and the protective effect of allopurinol. Magy Seb. 2005;58(2):134-137.
110. Bartels-Stringer M, Verpalen JT, Wetzels JF, et al. Iron chelation or anti-oxidants prevent renal cell damage in the rewarming phase after normoxic, but not hypoxic cold incubation. Cryobiology. 2007;54(3):258-264.
111. Peto K, Nemeth N, Brath E, et al. The effects of renal ischemia-reperfusion on hemorheological factors: preventive role of allopurinol. Clin Hemorheol Microcirc. 2007;37(4):347-358.
112. Monedero P, Garc-Fernndez N, Prez-Valdivieso JR, et al. Acute kidney injury. Rev Esp Anestesiol Reanim. 2011;58(6):365-374
113. Wang Z, Colli JL, Keel C, et al. Isoprostane: quantitation of renal ischemia and reperfusion injury after renal artery clamping in an animalmodel. J Endourol. 2012;26(1):21-25.